Bradley G. Somer MDMedical Oncologist; President, West Cancer Center and Research Institute; Associate Professor of Hematology/Oncology, University of Tennessee Health Science Center, Memphis, Tennessee
Dr. Brad Somer, a medical oncologist in Memphis, Tennessee, is the President of the West Cancer Center and Research Institute, where he has practiced since 2002 after completing his fellowship training in hematology/oncology at the University of Pennsylvania Cancer Center in Philadelphia. He is one of the leaders of the most renowned multi-disciplinary comprehensive cancer center servicing the mid-south. He also serves as an assistant professor of hematology/oncology at the University of Tennessee Health Science Center.
Dr. Somer, is actively involved in clinical research in the gastrointestinal/genitourinary clinical trials program. He also serves on the NCCN panel for kidney cancer.
Dr. Somer earned his medical degree from the Albert Einstein College of Medicine in New York, with a Distinction in Research. He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While at the University of Pennsylvania, he served as assistant editor of OncoLink, a leading and award-winning cancer information website. He received his MBA at U Mass Amherst with a healthcare focus in conjunction with the American Association of Physician Leadership.
Assistant Professor, Hematology/Oncology, University of Tennessee Health Science Center; Senior Partner, West Clinic, Memphis, Tennessee
MD: Albert Einstein College of Medicine, New York
Fellowship (hematology/oncology):University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
DisclosuresDr. Somer does not have any disclosures.
Recent Contributions to PracticeUpdate:
- FDA Expands Approval of Sutent to Reduce the Risk of Kidney Cancer Returning
- Advances in VEGF and Immuno-Oncology Therapies for Localized RCC
- 2017 Top Stories in RCC: CheckMate-214
- Characterization of Patients With Poor-Risk mRCC Shows Continued Poor Outcomes
- Survival of Patients With mRCC Continues to Improve in the Targeted Therapy Era
- ESMO 2017: Recommendations From Dr. Bradley Somer
- Coprimary Endpoint of Objective Response Rate Is Met for Nivolumab + Ipilimumab vs Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- MET Inhibitor Savolitinib in MET-Driven Advanced Papillary Renal Cell Carcinoma
- Nivolumab Combined With Ipilimumab Is Safe and Effective in mRCC
- Hemoglobin Level Increase as an Efficacy Biomarker During Axitinib Treatment for Metastatic Renal Cell Carcinoma